Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents

Jeanny B. Aragon-Ching; Yang Min Ning; Clara C. Chen; Lea Latham; Jean Pierre Guadagnini; James L. Gulley; Philip M. Arlen; John J. Wright; Howard Parnes; William D. Figg; William L. Dahut

doi:10.1080/07357900802208608

Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents

Jeanny B. Aragon-Ching, Yang Min Ning, Clara C. Chen, Lea Latham, Jean Pierre Guadagnini, James L. Gulley, Philip M. Arlen, John J. Wright, Howard Parnes, William D. Figg, William L. Dahut

Research output: Contribution to journal › Article › peer-review

109 Scopus citations

Abstract

ONJ is an important toxicity in cancer patients receiving bisphosphonate therapy. Here we report a higher than usual incidence of ONJ, 11 of 60 (18.3%, 95% Confidence Interval, CI: 9%-28%) patients enrolled in a phase II clinical trial combining bevacizumab, docetaxel, thalidomide, and prednisone (ATTP) in chemotherapy-naive men with metastatic castration resistant prostate cancer (mCRPC). The use of bisphosphonates was allowed at study entry. Our study suggests that anti-angiogenic and chemotherapy agents can predispose to the development of ONJ in men with mCRPC on zoledronic acid. Imaging modalities, such as bone scans, may be useful in following the clinical course of patients who develop ONJ.

Original language	English
Pages (from-to)	221-226
Number of pages	6
Journal	Cancer Investigation
Volume	27
Issue number	2
DOIs	https://doi.org/10.1080/07357900802208608
State	Published - Feb 2009
Externally published	Yes

Keywords

Anti-angiogenesis
Bisphosphonates
Chemotherapy
Osteonecrosis of the jaw
Prostate pancer

Access to Document

10.1080/07357900802208608

Cite this

Aragon-Ching, J. B., Ning, Y. M., Chen, C. C., Latham, L., Guadagnini, J. P., Gulley, J. L., Arlen, P. M., Wright, J. J., Parnes, H., Figg, W. D., & Dahut, W. L. (2009). Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Investigation, 27(2), 221-226. https://doi.org/10.1080/07357900802208608

@article{46166f8e86094a22a8921e9d785924be,

title = "Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents",

abstract = "ONJ is an important toxicity in cancer patients receiving bisphosphonate therapy. Here we report a higher than usual incidence of ONJ, 11 of 60 (18.3%, 95% Confidence Interval, CI: 9%-28%) patients enrolled in a phase II clinical trial combining bevacizumab, docetaxel, thalidomide, and prednisone (ATTP) in chemotherapy-naive men with metastatic castration resistant prostate cancer (mCRPC). The use of bisphosphonates was allowed at study entry. Our study suggests that anti-angiogenic and chemotherapy agents can predispose to the development of ONJ in men with mCRPC on zoledronic acid. Imaging modalities, such as bone scans, may be useful in following the clinical course of patients who develop ONJ.",

keywords = "Anti-angiogenesis, Bisphosphonates, Chemotherapy, Osteonecrosis of the jaw, Prostate pancer",

author = "Aragon-Ching, {Jeanny B.} and Ning, {Yang Min} and Chen, {Clara C.} and Lea Latham and Guadagnini, {Jean Pierre} and Gulley, {James L.} and Arlen, {Philip M.} and Wright, {John J.} and Howard Parnes and Figg, {William D.} and Dahut, {William L.}",

note = "Funding Information: This project has been supported by the Intramural Research Program of the National Cancer Institute, Center for Cancer Research, National Institutes of Health. The content of this publication does not reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.",

year = "2009",

month = feb,

doi = "10.1080/07357900802208608",

language = "English",

volume = "27",

pages = "221--226",

journal = "Cancer Investigation",

issn = "0735-7907",

number = "2",

}

Aragon-Ching, JB, Ning, YM, Chen, CC, Latham, L, Guadagnini, JP, Gulley, JL, Arlen, PM, Wright, JJ, Parnes, H, Figg, WD & Dahut, WL 2009, 'Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents', Cancer Investigation, vol. 27, no. 2, pp. 221-226. https://doi.org/10.1080/07357900802208608

TY - JOUR

T1 - Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents

AU - Aragon-Ching, Jeanny B.

AU - Ning, Yang Min

AU - Chen, Clara C.

AU - Latham, Lea

AU - Guadagnini, Jean Pierre

AU - Gulley, James L.

AU - Arlen, Philip M.

AU - Wright, John J.

AU - Parnes, Howard

AU - Figg, William D.

AU - Dahut, William L.

N1 - Funding Information: This project has been supported by the Intramural Research Program of the National Cancer Institute, Center for Cancer Research, National Institutes of Health. The content of this publication does not reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

PY - 2009/2

Y1 - 2009/2

N2 - ONJ is an important toxicity in cancer patients receiving bisphosphonate therapy. Here we report a higher than usual incidence of ONJ, 11 of 60 (18.3%, 95% Confidence Interval, CI: 9%-28%) patients enrolled in a phase II clinical trial combining bevacizumab, docetaxel, thalidomide, and prednisone (ATTP) in chemotherapy-naive men with metastatic castration resistant prostate cancer (mCRPC). The use of bisphosphonates was allowed at study entry. Our study suggests that anti-angiogenic and chemotherapy agents can predispose to the development of ONJ in men with mCRPC on zoledronic acid. Imaging modalities, such as bone scans, may be useful in following the clinical course of patients who develop ONJ.

AB - ONJ is an important toxicity in cancer patients receiving bisphosphonate therapy. Here we report a higher than usual incidence of ONJ, 11 of 60 (18.3%, 95% Confidence Interval, CI: 9%-28%) patients enrolled in a phase II clinical trial combining bevacizumab, docetaxel, thalidomide, and prednisone (ATTP) in chemotherapy-naive men with metastatic castration resistant prostate cancer (mCRPC). The use of bisphosphonates was allowed at study entry. Our study suggests that anti-angiogenic and chemotherapy agents can predispose to the development of ONJ in men with mCRPC on zoledronic acid. Imaging modalities, such as bone scans, may be useful in following the clinical course of patients who develop ONJ.

KW - Anti-angiogenesis

KW - Bisphosphonates

KW - Chemotherapy

KW - Osteonecrosis of the jaw

KW - Prostate pancer

UR - http://www.scopus.com/inward/record.url?scp=60849105693&partnerID=8YFLogxK

U2 - 10.1080/07357900802208608

DO - 10.1080/07357900802208608

M3 - Article

C2 - 19235596

AN - SCOPUS:60849105693

SN - 0735-7907

VL - 27

SP - 221

EP - 226

JO - Cancer Investigation

JF - Cancer Investigation

IS - 2

ER -

Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents

Abstract

Keywords

Access to Document

Fingerprint

Cite this